COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

COLADO, ANA; FERNÁNDEZ, JULIETA BELÉN; MOREIRA, ILEANA; CASSARINO, CHIARA; CURCIARELLO, RENATA; FERREYRA, MALENA; PÉREZ MILLÁN, MARÍA INÉS; IBAÑEZ, ITATÍ; DOCENA, GUILLERMO; ERRA, LORENZO; PAOLINI, MARÍA VIRGINIA; TAU, LORENA; VISHNOPOLSKA, SEBASTIÁN; VIJODITZ, GUSTAVO; RODRÍGUEZ, DIEGO; FERREYRA MUFARREGUE, LEILA ROMINA; QUIROGA, MARÍA FLORENCIA; POZNER, ROBERTO; BEZRODNIK, LILIANA; URIARTE, IGNACIO; SEMINARIO, GISELA; BERNATOWIEZ, JULIANA; RUMBO, MARTÍN; LÓPEZ, ANA LAURA; RIZZO, GASTÓN; BADANO, MARÍA NOEL; BARÉ, PATRICIA; BORGE, MERCEDES; ALMEJUN, MARÍA BELÉN

JOURNAL OF CLINICAL IMMUNOLOGY

SPRINGER/PLENUM PUBLISHERS

Lugar: New York; Año: 2022 vol. 43 p. 271 - 285

0271-9142

Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer vaccines, even though most of the data of humoral and cellular responses combination on available vaccines comes from trials conducted in healthy individuals. We aimed to evaluate the safety and immunogenicity of the different vaccines in IEI patients in Argentina.The study cohort included adults and pediatric IEI patients (n = 118) and age-matched healthy controls (HC) (n = 37). B cell response was evaluated by measuring IgG anti-spike/receptor binding domain (S/RBD) and anti-nucleocapsid(N) antibodies by ELISA. Neutralization antibodies were also assessed with an alpha-S protein-expressing pseudo-virus assay. The T cell response was analyzed by IFN-γ secretion on S- or N-stimulated PBMC by ELISPOT and the frequency of S-specific circulating T follicular-helper cells (TFH) was evaluated by flow cytometry.No moderate/severe vaccine-associated adverse events were observed. Anti-S/RBD titers showed significant differences in both pediatric and adult IEI patients versus the age-matched HC cohort (p